The Lancet: April 24, 2014

Marcia Brose discusses results of a phase III trial of the kinase inhibitor sorafenib for treating radioactive iodine-refractory thyroid cancer.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv